News & Updates
Filter by Specialty:

Infliximab trumps other biologics as maintenance drug in CD
Among the many biologics used to treat adults with moderate-to-severe Crohn’s disease (CD), infliximab subcutaneous (SC) 120 mg every 2 weeks (Q2W) demonstrates the highest efficacy in clinical remission during maintenance treatment of 52 to 64 weeks’ duration, according to the results of a recent study presented at CCC 2025.
Infliximab trumps other biologics as maintenance drug in CD
19 Feb 2025
OLE reflects long-term efficacy, safety of mirikizumab for CD
Initial findings from the ongoing VIVID-2 open-label extension (OLE) study comprising week 52 endoscopic responders from the phase III VIVID-1 trial demonstrate the long-term clinical and endoscopic efficacy of the selective anti-interleukin-23p19 monoclonal antibody mirikizumab for the treatment of moderate-to-severe active Crohn’s disease (CD).
OLE reflects long-term efficacy, safety of mirikizumab for CD
18 Feb 2025
SC dose escalation restores efficacy of infliximab in IBD patients
Escalating the dose of subcutaneous (SC) CT-P13, a biosimilar of infliximab, from 120 to 240 mg every 2 weeks appears to bring back the efficacy of the drug in patients with inflammatory bowel disease (IBD) who no longer respond to treatment, suggests a study presented at 2025 Crohn's & Colitis Congress.
SC dose escalation restores efficacy of infliximab in IBD patients
17 Feb 2025
DOACs for ICH survivors with atrial fibrillation? Stroke protection comes at a cost
For survivors of intracerebral haemorrhage (ICH) with atrial fibrillation (AF), the use of direct oral anticoagulants (DOACs) works to prevent ischaemic stroke events, but this benefit appears to be offset by major bleeding side effects, as shown in the open-label, phase III PRESTIGE-AF trial.